

Ligand-enabled γ -C–H Olefination and Carbonylation: Construction of β -Quaternary Carbon Centers

Suhua Li, Gang Chen, Chen-Guo Feng, Wei Gong and Jin-Quan Yu

Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, California 92037
















Table of Contents

1. General Information	S2
2. Experimental Section	S3–S29
2.1 Synthesis of Starting Materials	S3–S8
2.2 Synthesis of Quinoline Ligands	S8–S11
2.3 Optimization of Reaction Conditions	S12–S17
2.4 General Procedure for Olefination of Amides	S18–S26
2.5 Procedure for Cleavage of Auxiliary	S26–27
2.6 Procedure for Construction of poly-functionalized Quaternary Carbon Centers	S27–S29
3. References	S30
4. NMR Spectra of New Compounds	S31–S70

General Information: Octafluorotoluene was obtained from Oakwood Chemical. Other solvents and chemicals were from Sigma-Aldrich, Acros and Alfa Aesar and used directly without further purification. Analytical thin layer chromatography was performed on 0.25 mm silica gel 60-F254. Visualization was carried out with UV light and Vogel's permanganate. Preparative TLC was performed on 1.0 mm silica gel (Analtech). Columns for flash chromatography (FC) contained silica gel (32–63 μ , Dynamic Adsorbents, Inc.). ^1H NMR spectra were recorded on Bruker AV-400 instrument (400 MHz) or Varian Inova 400 (400 MHz), Bruker DRX-600 instrument (600 MHz). Chemical shifts were quoted in parts per million (ppm) referenced to 0.0 ppm for tetramethylsilane. The following abbreviations (or combinations thereof) were used to explain multiplicities: s = singlet, d = doublet, t = triplet, q = quartet, quint = quintet, sext = sextet, m = multiplet, br = broad. Coupling constants, J , were reported in Hertz unit (Hz). ^{13}C NMR spectra were recorded on Bruker DRX-600 instrument (150 MHz), and were fully decoupled by broad band proton decoupling. Chemical shifts were reported in ppm referenced to the center line of a triplet at 77.0 ppm of chloroform- d . In the ^{13}C NMR analysis, peaks that correspond to those of the polyfluoroarylamide auxiliary appeared as nearly invisible, complex sets of multiplets; they are omitted in the following spectroscopic analysis. High-resolution mass spectra (HRMS) were recorded on an Agilent Mass spectrometer using ESI-TOF (electrospray ionization-time of flight).


Experimental Section

2.1 Synthesis of Starting Materials




General Procedure for the Preparation of Amide Substrates:

An acid chloride (10 mmol), prepared from the corresponding carboxylic acid and oxalyl chloride, was added to a solution of 2,3,5,6-tetrafluoro-4-(trifluoromethyl)aniline (10 mmol) in toluene (10 mL). The reaction mixture was stirred for 12 h under reflux. After cooling to room temperature, the product mixture was concentrated in vacuum and was recrystallized from ethyl acetate/hexane to give the amide.




3,3-dimethyl-N-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)butanamide

^1H NMR (400 MHz, CDCl_3) δ 6.83 (br s, 1 H), 2.35 (s, 2 H), 1.13 (s, 9 H); ^{13}C NMR (150 MHz, CDCl_3) δ 169.3, 50.1, 31.3, 29.6; HRMS (ESI-TOF) Calcd for $\text{C}_{13}\text{H}_{13}\text{F}_7\text{NO}$ [M-H] $^-$: 330.0729; found: 330.0740.




3,3-dimethyl-N-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)pentanamide

^1H NMR (400 MHz, CDCl_3) δ 6.91 (br s, 1 H), 2.33 (s, 2 H), 1.44 (q, $J = 7.6$ Hz, 2 H), 1.07 (s, 6 H), 0.91 (t, $J = 7.4$ Hz, 3 H); ^{13}C NMR (150 MHz, CDCl_3) δ 169.8, 47.8, 34.8, 33.9, 26.5, 8.4; HRMS (ESI-TOF) Calcd for $\text{C}_{14}\text{H}_{15}\text{F}_7\text{NO}$ [M+H] $^+$: 346.1042; found: 346.1037.




3-ethyl-3-methyl-N-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)pentanamide

^1H NMR (400 MHz, CDCl_3) δ 6.91 (br s, 1 H), 2.33 (s, 2 H), 1.44 (q, $J = 7.5$ Hz, 4 H), 1.03 (s, 3 H), 0.88 (t, $J = 7.4$ Hz, 6 H); ^{13}C NMR (150 MHz, CDCl_3) δ 169.4, 45.4, 36.6, 31.1, 24.0, 8.1; HRMS (ESI-TOF) Calcd for $\text{C}_{15}\text{H}_{17}\text{F}_7\text{NO}$ $[\text{M}+\text{H}]^+$: 360.1198; found: 360.1189.




3-benzyl-3-methyl-N-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)pentanamide

^1H NMR (400 MHz, CDCl_3) δ 7.35-7.15 (m, 5 H), 7.01 (br s, 1 H), 2.79 (d, $J = 13.2$ Hz, 1 H), 2.70 (d, $J = 13.2$ Hz, 1 H), 2.32 (d, $J = 14.4$ Hz, 1 H), 2.25 (d, $J = 14.4$ Hz, 1 H), 1.58-1.41 (m, 2 H), 1.04 (s, 3 H), 0.98 (t, $J = 7.4$ Hz, 3 H); ^{13}C NMR (150 MHz, CDCl_3) δ 169.5, 138.1, 130.7, 128.0, 126.2, 44.9, 44.3, 37.6, 31.7, 24.2, 8.4; HRMS (ESI-TOF) Calcd for $\text{C}_{20}\text{H}_{19}\text{F}_7\text{NO}$ $[\text{M}+\text{H}]^+$: 422.1355; found: 422.1351.




3-cyclopentyl-3-methyl-N-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)pentanamide

^1H NMR (400 MHz, CDCl_3) δ 6.92 (br s, 1 H), 2.38 (s, 2 H), 2.09-1.97 (m, 1 H), 1.70-1.49 (m, 9 H), 1.40-1.25 (m, 2 H), 1.03 (s, 3 H), 0.95 (t, $J = 7.4$ Hz, 3 H); ^{13}C NMR (150 MHz, CDCl_3) δ 169.6, 47.1, 44.0, 38.4, 30.4, 26.8, 26.5, 25.7, 21.2, 8.3; HRMS (ESI-TOF) Calcd for $\text{C}_{18}\text{H}_{21}\text{F}_7\text{NO}$ $[\text{M}+\text{H}]^+$: 400.1511; found: 400.1500.




4-methoxy-3,3-dimethyl-N-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)butanamide

^1H NMR (400 MHz, CDCl_3) δ 8.46 (br s, 1 H), 3.46 (s, 3 H), 3.28 (s, 2 H), 2.49 (s, 2 H), 1.07 (s, 6 H); ^{13}C NMR (150 MHz, CDCl_3) δ 169.3, 81.2, 59.3, 46.4, 34.8, 25.7; HRMS (ESI-TOF) Calcd for $\text{C}_{14}\text{H}_{15}\text{F}_7\text{NO}_2$ $[\text{M}+\text{H}]^+$: 362.0991; found: 362.0991.




5-methoxy-3,3-dimethyl-N-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)pentanamide

^1H NMR (400 MHz, CDCl_3) δ 9.50 (br s, 1 H), 3.65 (t, $J = 5.0$ Hz, 2 H), 3.45 (s, 3 H), 2.48 (s, 2 H), 1.76 (t, $J = 5.2$ Hz, 2 H), 1.09 (s, 6 H); ^{13}C NMR (150 MHz, CDCl_3) δ 169.6, 70.2, 58.9, 47.7, 39.4, 33.0, 29.1; HRMS (ESI-TOF) Calcd for $\text{C}_{15}\text{H}_{17}\text{F}_7\text{NO}$ $[\text{M}+\text{H}]^+$: 376.1148; found: 376.1145.




2-(1-methylcyclopentyl)-N-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)acetamide

^1H NMR (400 MHz, CDCl_3) δ 6.93 (br s, 1 H), 2.46 (s, 2 H), 1.76-1.48 (m, 8 H), 1.15 (s, 3 H); ^{13}C NMR (150 MHz, CDCl_3) δ 169.7, 48.1, 41.9, 39.5, 25.7, 23.9; HRMS (ESI-TOF) Calcd for $\text{C}_{15}\text{H}_{15}\text{F}_7\text{NO}$ $[\text{M}+\text{H}]^+$: 358.1042; found: 358.1039.




2-(1-methylcyclohexyl)-N-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)acetamide

^1H NMR (400 MHz, CDCl_3) δ 6.95 (br s, 1 H), 2.37 (s, 2 H), 1.56-1.34 (m, 10 H), 1.11 (s, 3 H); ^{13}C NMR (150 MHz, CDCl_3) δ 169.1, 48.6, 37.9, 33.9, 26.0, 25.1, 22.0; HRMS (ESI-TOF) Calcd for $\text{C}_{16}\text{H}_{17}\text{F}_7\text{NO}$ $[\text{M}+\text{H}]^+$: 372.1198; found: 372.1185.




2-(1-methylcyclohexyl)-N-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)acetamide

^1H NMR (400 MHz, CDCl_3) δ 7.03 (br s, 1 H), 3.81-3.64 (m, 4 H), 2.44 (s, 2 H), 1.76-1.66 (m, 2 H), 1.58-1.49 (m, 2 H), 1.24 (s, 3 H); ^{13}C NMR (150 MHz, CDCl_3) δ 168.4, 63.7, 48.6, 37.6, 31.6, 23.7; HRMS (ESI-TOF) Calcd for $\text{C}_{15}\text{H}_{15}\text{F}_7\text{NO}$ $[\text{M}+\text{H}]^+$: 374.0991; found: 374.0991.




2-(4-methyl-1-(2,2,2-trifluoroacetyl)piperidin-4-yl)-N-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)acetamide

^1H NMR (400 MHz, CDCl_3) δ 7.48 (br s, 1 H), 4.02-3.92 (m, 1 H), 3.80-3.68 (m, 1 H), 3.56-3.37 (m, 2 H), 2.48 (d, $J = 13.6$ Hz, 1 H), 2.43 (d, $J = 13.6$ Hz, 1 H), 1.78-1.60 (m, 4 H), 1.27 (s, 3 H); ^{13}C NMR (150 MHz, CDCl_3) δ 168.1, 155.5 (q, $J = 35.6$ Hz), 116.5 (q, $J = 286.1$ Hz), 47.6, 42.1 (q, $J = 3.3$ Hz), 39.8, 37.1, 36.5, 32.5, 23.2; HRMS (ESI-TOF) Calcd for $\text{C}_{17}\text{H}_{15}\text{F}_{10}\text{N}_2\text{O}_2$ $[\text{M}+\text{H}]^+$: 469.0974; found: 469.0968.




3,3-dimethyl-N-(perfluorophenyl)butanamide

^1H NMR (400 MHz, CDCl_3) δ 6.70 (br s, 1 H), 2.31 (s, 2 H), 1.12 (s, 9 H); ^{13}C NMR (150 MHz, CDCl_3) δ 169.8, 50.1, 31.2, 29.7; HRMS (ESI-TOF) Calcd for $\text{C}_{12}\text{H}_{13}\text{F}_5\text{NO}$ $[\text{M}+\text{H}]^+$: 282.0917; found: 282.0910.



N-(4-cyano-2,3,5,6-tetrafluorophenyl)-3,3-dimethylbutanamide

^1H NMR (400 MHz, CDCl_3) δ 7.01 (br s, 1 H), 2.35 (s, 2 H), 1.12 (s, 9 H); ^{13}C NMR (150 MHz, CDCl_3) δ 169.4, 147.4 (ddt, $J_1 = 259.8$ Hz, $J_2 = 15.0$ Hz, $J_3 = 4.4$ Hz), 141.7 (ddt, $J_1 = 251.6$ Hz, $J_2 = 12.6$ Hz, $J_3 = 4.3$ Hz), 122.7 (t, $J = 14.2$ Hz), 107.3 (t, $J = 3.4$ Hz), 91.1 (t, $J = 2.2$ Hz), 50.0, 31.3, 29.6; HRMS (ESI-TOF) Calcd for $\text{C}_{13}\text{H}_{13}\text{F}_4\text{N}_2\text{O}$ $[\text{M}+\text{H}]^+$: 289.0964; found: 289.0969.




N-(3,5-bis(trifluoromethyl)phenyl)-3,3-dimethylbutanamide

^1H NMR (400 MHz, CDCl_3) δ 8.03 (s, 1 H), 7.59 (s, 1 H), 7.44 (s, 1 H), 2.27 (s, 2 H), 1.12 (s, 9 H); ^{13}C NMR (150 MHz, CDCl_3) δ 170.5, 139.2, 132.3 (q, $J = 33.3$ Hz), 123.0 (q, $J = 271.1$ Hz), 119.4, 117.5 (quint, $J = 3.8$ Hz), 51.5, 31.4, 29.7; HRMS (ESI-TOF) Calcd for $\text{C}_{14}\text{H}_{16}\text{F}_6\text{NO}$ $[\text{M}+\text{H}]^+$: 328.1136; found: 328.1132.

2.2 Synthesis of Quinoline Ligands

The ligand **L2**, **L7** ~ **15** were prepared according to the literature with small modifications.



1. Synthesis of **7**¹


A mixture of aniline (30 mmol), dioxinone (42 mmol), and NaOAc (30 mmol) in THF (6 mL) were heated under reflux for 24 h. After cooled to room temperature, the mixture was diluted with AcOEt, washed with H₂O and brine. The organic phase was dried with anhydrous Na₂SO₄, concentrated under reduced pressure, and purified by flash column chromatography (silica gel, hexane/EtOAc 5/1 to 2/1).

2. Synthesis of **8**²

To a 250 mL of round bottle flask were added **7** (20 mmol) and K₂CO₃ (46 mmol) and DMF (50 mL). After stirring for 1 h, 1,4-dibromobutane (22 mmol) was added. The reaction was stirred for additional 12 h (monitored by TLC) before it was poured into water (150 mL). The mixture was extracted with EtOAc (40 mL × 3). The combined organic layers was washed with HCl (3 M, 40 mL × 2) and brine, dried with Na₂SO₄, filtrated and concentrated under vacuum affording the crude product which could be used without further purification.

3. Synthesis of **L2, L7-15**²


To a 100 mL of round bottle were added **8** (~ 20 mmol) and 15 mL of H₂SO₄. The mixture was stirred at 50 °C until full conversion of **8** (about 1.5 hours). The reaction mixture was carefully poured into ammonia/ice (ammonia: 28%, 50 mL; ice: ~ 100 mL). The mixture was extracted with EtOAc (60 mL × 3). The combined organic layers was washed with brine, dried with MgSO₄, filtrated and concentrated affording the crude product which was purified by flash column chromatography (silica gel, hexane/EtOAc 4/1 to 1/1).



L9


8-methoxy-2,5-dimethyl-3,4-dihydro-2H-pyrano[2,3-b]quinoline (L9)

¹H NMR (600 MHz, CDCl₃) δ 7.74 (d, *J* = 9.6 Hz, 1 H), 7.18 (d, *J* = 2.4 Hz, 1 H), 7.00 (dd, *J*₁ = 9.0 Hz, *J*₂ = 2.4 Hz, 1 H), 4.38-4.31 (m, 1 H), 3.89 (s, 3 H), 2.93 (ddd, *J*₁ = 16.4 Hz, *J*₂ = 3.9 Hz, *J*₃ = 2.6 Hz, 1 H), 2.85-2.76 (m, 1 H), 2.48 (s, 3 H), 2.15-2.08 (m, 1 H), 1.82-1.73 (m, 1 H), 1.50 (d, *J* = 6.6 Hz, 3 H); ¹³C NMR (150 MHz, CDCl₃) δ 160.4, 160.2, 147.4, 144.1, 124.4, 120.0, 116.0, 113.4, 106.5, 73.0, 55.3, 29.0, 23.2, 21.3, 13.9; HRMS (ESI-TOF) Calcd for C₁₅H₁₈NO₂ [M+H]⁺: 244.1338; found: 244.1340.




2,5-dimethyl-7-(trifluoromethyl)-3,4-dihydro-2H-pyrano[2,3-*b*]quinolone (L10)

^1H NMR (400 MHz, CDCl_3) δ 8.18 (s, 1 H), 7.91 (d, $J = 8.8$ Hz, 1 H), 7.74 (d, $J = 8.8$ Hz, 1 H), 4.48-4.37 (m, 1 H), 3.08-2.82 (m, 2 H), 2.60 (s, 3 H), 2.23-2.13 (m, 1 H), 1.90-1.76 (m, 1 H), 1.54 (d, $J = 6.4$ Hz, 3 H); ^{13}C NMR (150 MHz, CDCl_3) δ 161.4, 147.2, 145.0, 128.9, 125.5 (q, $J = 32.1$ Hz), 124.6 (q, $J = 3.0$ Hz), 124.5 (q, $J = 270.3$ Hz), 124.1, 121.3 (q, $J = 4.4$ Hz), 117.7, 73.6, 28.7, 23.5, 21.3, 14.0; HRMS (ESI-TOF) Calcd for $\text{C}_{15}\text{H}_{15}\text{F}_3\text{NO}$ $[\text{M}+\text{H}]^+$: 282.1106; found: 282.1113.



9-fluoro-2,5-dimethyl-3,4-dihydro-2H-pyrano[2,3-*b*]quinolone (L11)


^1H NMR (400 MHz, CDCl_3) δ 7.69-7.62 (m, 1 H), 7.30-7.25 (m, 2 H), 4.45-4.35 (m, 1 H), 3.01 (ddd, $J_1 = 16.9$ Hz, $J_2 = 5.3$ Hz, $J_3 = 2.9$ Hz, 1 H), 2.94-2.83 (m, 1 H), 2.56 (s, 3 H), 2.20-2.12 (m, 1 H), 1.88-1.76 (m, 1 H), 1.52 (d, $J = 6.4$ Hz, 3 H); ^{13}C NMR (150 MHz, CDCl_3) δ 160.1, 157.0 (d, $J = 252.6$ Hz), 144.3 (d, $J = 2.7$ Hz), 135.9 (d, $J = 11.4$ Hz), 126.9 (d, $J = 2.6$ Hz), 123.0 (d, $J = 7.7$ Hz), 118.8 (d, $J = 4.5$ Hz), 117.3, 112.9 (d, $J = 18.5$ Hz), 73.3, 28.7, 23.6, 21.3, 14.2; HRMS (ESI-TOF) Calcd for $\text{C}_{14}\text{H}_{15}\text{FNO}$ $[\text{M}+\text{H}]^+$: 232.1138; found: 232.1140.



2,5-dimethyl-8-(trifluoromethyl)-3,4-dihydro-2H-pyrano[2,3-*b*]quinolone (L12)


^1H NMR (400 MHz, CDCl_3) δ 8.09 (s, 1 H), 7.97 (d, $J = 8.8$ Hz, 1 H), 7.53 (d, $J = 8.8$ Hz, 1 H), 4.48-4.34 (m, 1 H), 3.10-2.80 (m, 2 H), 2.56 (s, 3 H), 2.24-2.10 (m, 1 H), 1.90-1.76 (m, 1 H), 1.53 (d, $J = 6.4$ Hz, 3 H); ^{13}C NMR (150 MHz, CDCl_3) δ 160.8, 144.9, 144.1, 130.5 (q, $J = 32.3$ Hz), 126.7, 125.5 (q, $J = 4.2$

Hz), 124.4, 124.1 (q, $J = 270.6$ Hz), 119.3 (q, $J = 2.9$ Hz), 118.5, 73.5, 28.6, 23.6, 21.3, 14.0; Calcd for $C_{15}H_{15}F_3NO$ $[M+H]^+$: 282.1106; found: 282.1105.



8-(*tert*-butyl)-2,5-dimethyl-3,4-dihydro-2H-pyrano[2,3-*b*]quinolone (L14)

1H NMR (400 MHz, $CDCl_3$) δ 7.83-7.77 (m, 2 H), 7.45 (dd, $J_1 = 9.0$ Hz, $J_2 = 1.8$ Hz, 1 H), 4.42-4.28 (m, 1 H), 2.96 (ddd, $J_1 = 16.8$ Hz, $J_2 = 5.6$ Hz, $J_3 = 2.8$ Hz, 1 H), 2.90-2.78 (m, 1 H), 2.51 (s, 3 H), 2.16-2.07 (m, 1 H), 1.86-1.72 (m, 1 H), 1.50 (d, $J = 6.0$ Hz, 3 H), 1.39 (s, 9 H); ^{13}C NMR (150 MHz, $CDCl_3$) δ 160.0, 151.9, 145.7, 143.7, 123.5, 123.0, 122.7, 122.3, 115.3, 73.0, 34.8, 31.1, 29.0, 23.3, 21.3, 13.7; HRMS (ESI-TOF) Calcd for $C_{18}H_{24}NO$ $[M+H]^+$: 270.1858; found: 270.1861.




7-(*tert*-butyl)-2,5-dimethyl-3,4-dihydro-2H-pyrano[2,3-*b*]quinoline (L15)

1H NMR (400 MHz, $CDCl_3$) δ 7.80 (d, $J = 2.4$ Hz, 1 H), 7.77 (d, $J = 8.8$ Hz, 1 H), 7.66 (dd, $J_1 = 9.0$ Hz, $J_2 = 1.8$ Hz, 1 H), 4.41-4.31 (m, 1 H), 2.99 (ddd, $J_1 = 16.8$ Hz, $J_2 = 5.6$ Hz, $J_3 = 2.8$ Hz, 1 H), 2.92-2.80 (m, 1 H), 2.56 (s, 3 H), 2.18-2.09 (m, 1 H), 1.87-1.74 (m, 1 H), 1.51 (d, $J = 6.4$ Hz, 3 H), 1.41 (s, 9 H); ^{13}C NMR (150 MHz, $CDCl_3$) δ 159.6, 146.3, 143.97, 143.95, 127.5, 124.5, 118.1, 115.9, 73.0, 34.9, 31.4, 29.0, 23.6, 21.4, 13.8; HRMS (ESI-TOF) Calcd for $C_{18}H_{24}NO$ $[M+H]^+$: 270.1858; found: 270.1856.


2.3 Optimization of Reaction Conditions

General: The reactions were conducted using 0.1 mmol of substrate **1a** in the indicated conditions in 1 mL of solvent. The temperature is the oil bath temperature. All yields were determined by ^1H NMR using CH_2Br_2 as internal standard.

Ligand Screening




Solvent Screening:




Entry	Solvent	NMR Yield (%)
1	C ₆ F ₅ CF ₃	45
2	PhCF ₃	16
3	C ₆ F ₆	30
4	Hex	33
5	Toluene	37
6	DCE	28
7	<i>t</i> -AmylOH	32
8	<i>t</i> -BuOH	35
9	DMF	Trace
10	DMSO	0
11	EA	19
12	Hexafluoro-2-propanol	Trace
13	THF	16
14	Dioxane	27

Ag Salt Screening:




Entry	Ag	NMR yield (%)
1	AgOAc	45
2	Ag_3PO_4	11
3	Ag_2O	25
4	AgO	12
5	AgTFA	trace
6	AgOPiv	27

Base Effect:




Entry	Base	NMR Yield (%)
1	$\text{Na}_2\text{HPO}_4 \cdot 6\text{H}_2\text{O}$	29
2	NaOAc	29
3	NaHCO_3	28
4	NaOTs	40
5	Na_2CO_3	33
6	K_2HPO_4	45

Auxiliary Groups:




Amount of K_2HPO_4 :




Entry	K_2HPO_4 (Equiv)	NMR Yield (%)
1	1.1	71
2	2	71
3	3	67

Additional Base:





Entry	Base	NMR Yield (%)
1	-	71
2	Li ₂ CO ₃ (1 equiv)	64
3	Na ₂ CO ₃ (1 equiv)	77
4	K ₂ CO ₃ (1 equiv)	58
5	NaHCO ₃ (2 equiv)	82
6	NaHCO ₃ (2 equiv) (without K ₂ HPO ₄)	63
7	KHCO ₃	64
8	NaOTs	68
9	LiOAc	72
10	CsF	32
11	K ₃ PO ₄ (1 equiv)	71
12	LiCl	39
13	NaOAc	51
14	Na ₂ HPO ₄ ·7H ₂ O	67
15	NaTFA	52
16	NaCl	69
17	NaNO ₂	45

TEMPO and O₂:




with 20 mol% of TEMPO: 90% (NMR)
with 10 mol% of TEMPO: 95% (NMR)

Ligand Screening in γ -carbonylation reaction:




^a *t*-butyl peroxide (2 equiv) was used instead of TEMPO in 150 °C. ^b Neither TEMPO nor *t*-butyl peroxide was used.

2.4 General Procedure for the Olefination of Amides




To an oven dried 50 mL Schlenk-type tube (with a Teflon high pressure valve and side arm) equipped with a magnetic stir bar were added substrate **1a** (33.1 mg, 0.1 mmol), Pd(OAc)₂ (2.3 mg, 0.01 mmol), **L15** (10.7 mg, 0.04 mmol), TEMPO (1.6 mg, 0.01 mmol), AgOAc (33.4 mg, 0.2 mmol), K₂HPO₄ (19.2 mg, 0.11 mmol), NaHCO₃ (16.8 mg, 0.2 mmol), and 1 mL of C₆F₅CF₃ followed by 0.05 mL of ethyl acrylate. The mixture was frozen with a dry ice/acetone bath. The reaction tube was evacuated and back-filled with O₂ (3 times, balloon) and heated to 120 °C for 20 hours under vigorous stirring. Upon completion, the reaction mixture was cooled to room temperature. The reaction mixture was diluted with ethyl acetate and then filtered through a small pad of Celite. The solvents were removed under reduced pressure and the resulting mixture was purified by preparative TLC using hexanes/EtOAc as the eluent.




Ethyl 2-(4,4-dimethyl-6-oxo-1-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)piperidin-2-yl)acetate (2a)

Substrate **1a** was olefinated following the general procedure. After purification by preparative TLC (eluent: hexanes/EtOAc = 5/1), **2a** was obtained as a white solid (37.3 mg, 87%). ¹H NMR (400 MHz, CDCl₃) δ 4.35 (sext, *J* = 5.8 Hz, 1 H), 4.05-3.91 (m, 2 H), 2.50-2.34 (m, 4 H), 1.99 (ddd, *J*₁ = 13.6 Hz, *J*₂ = 4.6 Hz, *J*₃ = 2.0 Hz, 1 H), 1.71 (dd, *J*₁ = 13.6 Hz, *J*₂ = 11.2 Hz, 1 H), 1.19 (t, *J* = 7.2 Hz, 3 H), 1.13 (s, 3 H); ¹³C NMR (150 MHz, CDCl₃) δ 170.1, 169.8, 61.1, 53.6 (d, *J* = 2.9 Hz), 45.7, 42.0, 40.3, 30.4, 29.8, 24.5, 13.9; HRMS (ESI-TOF) Calcd for C₁₈H₁₉F₇NO₃ [M+H]⁺: 430.1253; found: 430.1254.




Ethyl 2-(4-ethyl-4-methyl-6-oxo-1-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)piperidin-2-yl)acetate (2b)

Substrate **1b** was olefinated following the general procedure. After purification by preparative TLC (eluent: hexanes/EtOAc = 5/1), **2b** was obtained as colorless oil (30.1 mg, 68%). The isomeric ratio (major/minor) was determined to be 56:44 by ^1H NMR. ^1H NMR (400 MHz, CDCl_3) δ 4.45-4.23 (m, 1 H), 4.06-3.91 (m, 2 H), 2.54-2.30 (m, 4 H), 2.12 (ddd, $J_1 = 13.8$ Hz, $J_2 = 5.0$ Hz, $J_3 = 3.0$ Hz, 0.44 H), 1.97 (ddd, $J_1 = 13.6$ Hz, $J_2 = 5.2$ Hz, $J_3 = 2.5$ Hz, 0.56 H), 1.68-1.36 (m, 3 H), 1.23-1.16 (m, 3 H), 1.14 (s, 1.68 H), 1.05 (s, 1.33 H), 1.00-0.87 (m, 3 H); ^{13}C NMR (150 MHz, CDCl_3) δ 170.4, 170.2, 169.80, 169.75, 61.1, 53.4 (d, $J = 2.9$ Hz), 53.2 (d, $J = 2.9$ Hz), 44.8, 43.8, 40.4, 40.3, 40.0, 39.6, 35.7, 32.44, 32.37, 29.4, 26.3, 21.4, 13.93, 13.91, 8.1, 7.6; HRMS (ESI-TOF) Calcd for $\text{C}_{19}\text{H}_{21}\text{F}_7\text{NO}_3$ $[\text{M}+\text{H}]^+$: 444.1410; found: 444.1420.




Ethyl 2-(4,4-diethyl-6-oxo-1-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)piperidin-2-yl)acetate (2c)

Substrate **1c** was olefinated following the general procedure. After purification by preparative TLC (eluent: hexanes/EtOAc = 5/1), **2c** was obtained as colorless oil (32.1 mg, 70%). ^1H NMR (400 MHz, CDCl_3) δ 4.29 (sext, $J = 5.8$ Hz, 1 H), 4.08-3.94 (m, 2 H), 2.53-2.27 (m, 4 H), 2.08 (ddd, $J_1 = 13.7$ Hz, $J_2 = 4.8$ Hz, $J_3 = 3.2$ Hz, 1 H), 1.62-1.50 (m, 3 H), 1.48-1.31 (m, 2 H), 1.20 (t, $J = 7.2$ Hz, 3 H), 0.96-0.84 (m, 6 H); ^{13}C NMR (150 MHz, CDCl_3) δ 170.4, 169.7, 61.0, 53.0 (d, $J = 2.9$ Hz), 42.6, 40.3, 37.8, 34.8, 30.7, 25.6, 13.9, 7.5, 7.1; HRMS (ESI-TOF) Calcd for $\text{C}_{20}\text{H}_{23}\text{F}_7\text{NO}_3$ $[\text{M}+\text{H}]^+$: 458.1566; found: 458.1567.




Ethyl 2-(4-benzyl-4-ethyl-6-oxo-1-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)piperidin-2-yl)acetate (2d)

Substrate **1d** was olefinated following the general procedure. After purification by preparative TLC (eluent: hexanes/EtOAc = 5/1), **2d** was obtained as yellow oil (25.2 mg, 49%). The isomeric ratio (major/minor) was determined to be 54:46 by ^1H NMR. ^1H NMR (400 MHz, CDCl_3) δ 7.37-7.23 (m, 3 H), 7.20-7.09 (m, 2 H), 4.62-4.51 (m, 0.46 H), 4.32-4.22 (m, 0.54 H), 4.06-3.94 (m, 2 H), 2.88 (d, $J = 13.6$ Hz, 0.47 H), 2.80 (d, $J = 13.6$ Hz, 0.47 H), 2.70 (d, $J = 13.6$ Hz, 0.53 H), 2.65 (d, $J = 13.6$ Hz, 0.53 H), 2.56-2.30 (m, 4 H), 2.14 (ddd, $J_1 = 13.8$ Hz, $J_2 = 5.0$ Hz, $J_3 = 3.2$ Hz, 0.54 H), 2.05 (ddd, $J_1 = 13.8$ Hz, $J_2 = 5.5$ Hz, $J_3 = 2.9$ Hz, 0.46 H), 1.75-1.50 (m, 1.82 H), 1.40-1.31 (m, 1.18 H), 1.23-1.15 (m, 3 H), 1.10 (t, $J = 7.4$ Hz, 1.59 H), 0.98 (t, $J = 7.4$ Hz, 1.41 H); ^{13}C NMR (150 MHz, CDCl_3) δ 170.34, 170.27, 169.71, 169.68, 136.7, 136.2, 130.5, 130.4, 128.3, 126.8, 126.6, 61.12, 61.07, 53.37 (d, $J = 2.9$ Hz), 52.85 (d, $J = 2.9$ Hz), 44.1, 42.4, 41.5, 40.6, 40.2, 39.8, 37.5, 37.0, 36.5, 35.9, 30.9, 27.0, 13.9, 7.9, 7.5; HRMS (ESI-TOF) Calcd for $\text{C}_{25}\text{H}_{25}\text{F}_7\text{NO}_3$ $[\text{M}+\text{H}]^+$: 520.1723; found: 520.1724.




Ethyl 2-(4-cyclopentyl-4-ethyl-6-oxo-1-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)piperidin-2-yl)acetate (2e)

Substrate **1e** was olefinated following the general procedure. After purification by preparative TLC (eluent: hexanes/EtOAc = 5/1), **2e** was obtained as colorless oil (25.6 mg, 51%). The isomeric ratio (major/minor) was determined to be 55:45 by ^1H NMR. ^1H NMR (400 MHz, CDCl_3) δ 4.40-4.31 (m, 0.45 H), 4.30-4.22 (m, 0.55 H), 4.06-3.96 (m, 2 H), 2.55-2.30 (m, 4 H), 2.23-1.95 (m, 2 H), 1.78-1.50 (m, 8 H), 1.47-1.23 (m, 3 H), 1.20 (t, $J = 7.2$ Hz, 3 H), 1.00-0.88 (m, 3 H); ^{13}C NMR (150 MHz, CDCl_3) δ 171.3, 171.1, 169.78, 169.75, 61.09, 61.06, 53.5 (d, $J = 2.3$ Hz), 52.8 (d, $J = 2.6$ Hz), 45.0, 44.7, 40.6, 40.3, 40.1, 39.1, 36.6, 36.5, 35.5, 27.7, 27.5, 26.4, 26.3, 26.2, 25.9, 25.6, 25.54, 25.49, 25.4, 13.9, 8.0, 7.5; HRMS (ESI-TOF) Calcd for $\text{C}_{23}\text{H}_{27}\text{F}_7\text{NO}_3$ $[\text{M}+\text{H}]^+$: 498.1879; found: 498.1888.



Ethyl 2-(4-(methoxymethyl)-4-methyl-6-oxo-1-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)piperidin-2-yl)acetate (2f)


Substrate **1f** was olefinated following the general procedure. After purification by preparative TLC (eluent: hexanes/EtOAc = 3/1), **2f** was obtained as yellow oil (28.3 mg, 62%). The isomeric ratio (major/minor) was determined to be 61:39 by ^1H NMR. ^1H NMR (400 MHz, CDCl_3) δ 4.45-4.30 (m, 1 H), 4.05-3.90 (m, 2 H), 3.45-3.90 (m, 5 H), 2.72-2.16 (m, 4 H), 2.00-1.85 (m, 1.39 H), 1.72-1.64 (m, 0.61 H), 1.25-1.06 (m, 6 H); ^{13}C NMR (150 MHz, CDCl_3) δ 170.3, 170.1, 169.85, 169.77, 80.8, 78.5, 61.1, 61.0, 59.4, 59.3, 53.5 (d, $J = 2.9$ Hz), 53.2 (d, $J = 2.7$ Hz), 41.8, 40.6, 40.9, 40.32, 40.30, 38.6, 37.0, 34.1, 34.0, 26.0, 20.7, 13.9; HRMS (ESI-TOF) Calcd for $\text{C}_{19}\text{H}_{21}\text{F}_7\text{NO}_4$ $[\text{M}+\text{H}]^+$: 460.1359; found: 460.1359.



Ethyl 2-(4-(2-methoxyethyl)-4-methyl-6-oxo-1-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)piperidin-2-yl)acetate (2g)


Substrate **1g** was olefinated following the general procedure. After purification by preparative TLC (eluent: hexanes/EtOAc = 3/1), **2g** was obtained as colorless oil (24.2 mg, 51%). The isomeric ratio (major/minor) was determined to be 52:48 by ^1H NMR. ^1H NMR (400 MHz, CDCl_3) δ 4.45-4.30 (m, 1 H), 4.06-3.90 (m, 2 H), 3.56-3.46 (m, 2 H), 3.33 (s, 3 H), 2.60-2.31 (m, 4 H), 2.19 (ddd, $J_1 = 13.7$ Hz, $J_2 = 4.5$ Hz, $J = 3.3$ Hz, 0.48 Hz), 2.07 (ddd, $J_1 = 13.7$ Hz, $J_2 = 4.7$ Hz, $J = 2.3$ Hz, 0.52 Hz), 1.90-1.64 (m, 3 H), 1.27-1.09 (m, 6 H); ^{13}C NMR (150 MHz, CDCl_3) δ 170.0, 169.9, 169.8, 169.7, 68.8, 68.6, 61.1, 61.0, 58.7, 58.6, 53.3 (d, $J = 2.9$ Hz), 53.2 (d, $J = 2.9$ Hz), 45.4, 44.5, 42.2, 40.6, 40.30, 40.28, 36.0, 31.92,

31.89, 27.2, 22.2, 13.92, 13.89.; HRMS (ESI-TOF) Calcd for C₂₀H₂₃F₇NO₄ [M+H]⁺: 474.1515; found: 474.1516.




Ethyl 2-(9-oxo-8-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)-8-azaspiro[4.5]decan-7-yl)acetate (2i)

Substrate **1i** was olefinated following the general procedure. After purification by preparative TLC (eluent: hexanes/EtOAc = 5/1), **2i** was obtained as white solid (30.0 mg, 66%). ¹H NMR (400 MHz, CDCl₃) δ 4.31 (sext, *J* = 5.8 Hz, 1 H), 4.05-3.92 (m, 2 H), 2.59-2.38 (m, 4 H), 2.05 (ddd, *J*₁ = 13.5 Hz, *J*₂ = 4.3 Hz, *J*₃ = 2.9 Hz, 1 H), 1.85 (dd, *J*₁ = 13.6 Hz, *J*₂ = 11.2 Hz, 1 H), 1.81-1.50 (m, 8 H), 1.19 (t, *J* = 7.2 Hz, 3 H); ¹³C NMR (150 MHz, CDCl₃) δ 170.3, 169.8, 61.1, 54.2 (d, *J* = 2.9 Hz), 44.1, 40.6, 40.4, 40.3, 40.0, 34.7, 24.4, 23.8, 13.9; HRMS (ESI-TOF) Calcd for C₂₀H₂₁F₇NO₃ [M+H]⁺: 456.1410; found: 456.1411.




Ethyl 2-(4-oxo-3-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)-3-azaspiro[5.5]undecan-2-yl)acetate (2j)

Substrate **1j** was olefinated following the general procedure. After purification by preparative TLC (eluent: hexanes/EtOAc = 5/1), **2j** was obtained as white solid (32.1 mg, 68%). ¹H NMR (400 MHz, CDCl₃) δ 4.32 (sext, *J* = 5.8 Hz, 1 H), 4.05-3.92 (m, 2 H), 2.64 (dd, *J*₁ = 17.2 Hz, *J*₂ = 3.2 Hz, 1 H), 2.50-2.38 (m, 2 H), 2.32-2.17 (m, 2 H), 1.65-1.35 (m, 11 H), 1.19 (t, *J* = 7.2 Hz, 3 H); ¹³C NMR (150 MHz, CDCl₃) δ 170.1, 169.8, 61.0, 52.8 (d, *J* = 2.9 Hz), 43.6, 40.3, 39.5, 39.1, 32.7, 32.4, 25.9, 21.6, 21.4, 13.9; HRMS (ESI-TOF) Calcd for C₂₁H₂₃F₇NO₃ [M+H]⁺: 470.1566; found: 470.1569.




Ethyl 2-(10-oxo-9-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)-3-oxa-9-azaspiro[5.5]undecan-8-yl)acetate (2k)

Substrate **1k** was olefinated following the general procedure. After purification by preparative TLC (eluent: hexanes/EtOAc = 3/1), **2k** was obtained as yellow oil (39.2 mg, 83%). ¹H NMR (400 MHz, CDCl₃) δ 4.34 (sext, *J* = 5.8 Hz, 1 H), 4.08-3.92 (m, 2 H), 3.84-3.62 (m, 4 H), 2.83 (dd, *J*₁ = 17.2 Hz, *J*₂ = 3.2 Hz, 1 H), 2.55-2.41 (m, 2 H), 2.35 (d, *J* = 17.2 Hz, 1 H), 2.28 (ddd, *J*₁ = 14.0 Hz, *J*₂ = 5.2 Hz, *J*₃ = 3.2 Hz, 1 H), 1.90-1.45 (m, 5 H), 1.20 (t, *J* = 7.0 Hz, 3 H); ¹³C NMR (150 MHz, CDCl₃) δ 169.6, 169.2, 63.3, 63.1, 61.2, 52.4 (d, *J* = 2.9 Hz), 42.5, 40.1, 39.7, 38.4, 32.8, 30.4, 13.9; HRMS (ESI-TOF) Calcd for C₂₀H₂₁F₇NO₄ [M+H]⁺: 472.1359; found: 472.1361.




Ethyl 2-(4-oxo-3-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)-9-(2,2,2-trifluoroacetyl)-3,9-diazaspiro[5.5]undecan-2-yl)acetate (2l)

Substrate **1l** was olefinated following the general procedure. After purification by preparative TLC (eluent: hexanes/EtOAc = 2/1), **2l** was obtained as yellow oil (42.5 mg, 75%). The isomeric ratio (major/minor) was determined to be 1:1 by ¹³C NMR. ¹H NMR (400 MHz, CDCl₃) δ 4.32 (hept, *J* = 6.0 Hz, 1 H), 4.08-3.96 (m, 2 H), 3.95-3.85 (m, 1 H), 3.80-3.65 (m, 1 H), 3.65-3.50 (m, 2 H), 2.78 (dd, *J*₁ = 17.2 Hz, *J*₂ = 3.2 Hz, 1 H), 2.55-2.37 (m, 3 H), 2.31-2.22 (m, 1 H), 1.86-1.72 (m, 3 H), 1.69-1.59 (m, 2 H), 1.20 (t, *J* = 7.2 Hz, 3 H); ¹³C NMR (150 MHz, CDCl₃) δ 169.5, 169.4, 168.54, 168.51, 155.4 (q, *J* = 35.6 Hz), 155.3 (q, *J* = 35.6 Hz), 116.4 (q, *J* = 286.1 Hz), 61.32, 61.30, 52.5 (d, *J* = 2.9 Hz), 52.4 (d, *J* = 2.7 Hz), 41.9, 41.7, 41.6, 41.38, 41.36, 39.8, 39.3, 39.1, 39.0, 38.9, 38.2, 37.2, 32.5, 31.5, 31.4, 31.3, 13.9; HRMS (ESI-TOF) Calcd for C₂₂H₂₁F₁₀N₂O₄ [M+H]⁺: 567.1342; found: 567.1345.




Benzyl 2-(4,4-dimethyl-6-oxo-1-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)piperidin-2-yl)acetate (2aa)

Substrate **1a** was olefinated following the general procedure. After purification by preparative TLC (eluent: hexanes/EtOAc = 3/1), **2aa** was obtained as yellow oil (39.2 mg, 83%). ^1H NMR (400 MHz, CDCl_3) δ 7.40-7.26 (m, 5 H), 4.99 (s, 2 H), 4.31 (sext, $J = 5.8$ Hz, 1 H), 2.54-2.30 (m, 4 H), 1.93 (ddd, $J_1 = 13.7$ Hz, $J_2 = 5.1$ Hz, $J_3 = 2.5$ Hz, 1 H), 1.72-1.64 (m, 1 H), 1.15 (s, 3 H), 1.09 (s, 3 H); ^{13}C NMR (150 MHz, CDCl_3) δ 170.1, 169.4, 134.9, 128.65, 128.63, 128.47, 66.8, 53.5 (d, $J = 2.9$ Hz), 45.7, 41.7, 40.1, 30.4, 29.7, 24.4; HRMS (ESI-TOF) Calcd for $\text{C}_{23}\text{H}_{21}\text{F}_7\text{NO}_3$ $[\text{M}+\text{H}]^+$: 492.1410; found: 492.1410.




4,4-dimethyl-6-(2-oxobutyl)-1-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)piperidin-2-one (2ab)

Substrate **1a** was olefinated following the general procedure. After purification by preparative TLC (eluent: hexanes/EtOAc = 3/1), **2ab** was obtained as colorless oil (26.4 mg, 64%). ^1H NMR (400 MHz, CDCl_3) δ 4.42 (sext, $J = 5.8$ Hz, 1 H), 2.55 (d, $J = 6.0$ Hz, 2 H), 2.44-2.24 (m, 4 H), 2.00 (ddd, $J_1 = 13.6$ Hz, $J_2 = 5.1$ Hz, $J_3 = 2.6$ Hz, 1 H), 1.54 (dd, $J_1 = 13.0$ Hz, $J_2 = 11.8$ Hz, 1 H), 1.19 (s, 3 H), 1.11 (s, 3 H), 0.94 (t, $J = 7.4$ Hz, 3 H); ^{13}C NMR (150 MHz, CDCl_3) δ 207.2, 170.3, 52.7 (d, $J = 2.9$ Hz), 47.6, 45.8, 42.1, 36.7, 30.5, 29.8, 24.5, 7.2; HRMS (ESI-TOF) Calcd for $\text{C}_{18}\text{H}_{19}\text{F}_7\text{NO}_2$ $[\text{M}+\text{H}]^+$: 414.1304; found: 414.1305.



4,4-dimethyl-6-(2-oxo-2-phenylethyl)-1-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)piperidin-2-one (2ac)


Substrate **1a** was olefinated following the general procedure. After purification by preparative TLC (eluent: hexanes/EtOAc = 3/1), **2ac** was obtained as white solid (32.2 mg, 70%). ¹H NMR (400 MHz, CDCl₃) δ 7.79-7.72 (m, 2 H), 7.62-7.55 (m, 1 H), 7.50-7.40 (m, 2 H), 4.70 (sext, *J* = 5.7 Hz, 1 H), 3.22 (dd, *J*₁ = 17.0 Hz, *J*₂ = 5.8 Hz, 1 H), 2.96 (dd, *J*₁ = 16.8 Hz, *J*₂ = 5.6 Hz, 1 H), 2.48-2.37 (m, 2 H), 2.08 (ddd, *J*₁ = 13.6 Hz, *J*₂ = 5.2 Hz, *J*₃ = 2.4 Hz, 1 H), 1.70 (dd, *J*₁ = 13.6 Hz, *J*₂ = 11.2 Hz, 1 H), 1.23 (s, 3 H), 1.13 (s, 3 H); ¹³C NMR (150 MHz, CDCl₃) δ 196.1, 170.2, 135.8, 134.0, 128.8, 127.6, 53.7 (d, *J* = 2.7 Hz), 45.8, 43.5, 42.6, 30.5, 29.9, 24.5; HRMS (ESI-TOF) Calcd for C₂₂H₁₉F₇NO₂ [M+H]⁺: 462.1298; found: 462.1299.



2-(4,4-dimethyl-6-oxo-1-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)piperidin-2-yl)acetonitrile (2ad)

Substrate **1a** was olefinated following the general procedure. After purification by preparative TLC (eluent: hexanes/EtOAc = 3/1), **2ad** was obtained as white solid (27.9 mg, 73%). ¹H NMR (400 MHz, CDCl₃) δ 4.17 (sext, *J* = 5.1 Hz, 1 H), 2.55-2.35 (m, 4 H), 2.09 (ddd, *J*₁ = 13.8 Hz, *J*₂ = 5.2 Hz, *J*₃ = 1.8 Hz, 1 H), 1.87 (t, *J* = 12.6 Hz, 1 H), 1.19 (s, 6 H); ¹³C NMR (150 MHz, CDCl₃) δ 169.7, 115.2, 52.9 (d, *J* = 3.8 Hz), 45.5, 41.5, 30.2, 29.8, 24.30, 24.28; HRMS (ESI-TOF) Calcd for C₁₆H₁₄F₇N₂O [M+H]⁺: 383.0994; found: 383.0983.

Gram Scale Synthesis




Ethyl 2-(4,4-dimethyl-6-oxo-1-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)piperidin-2-yl)acetate (2a)

To an oven dried 350 mL Schlenk-type tube (with a Teflon high pressure valve and side arm) equipped with a magnetic stir bar were added substrate **1a** (1.3202 g, 4.0 mmol), Pd(OAc)₂ (89.0 mg, 0.4 mmol), **L15** (431.1 mg, 1.6 mmol), TEMPO (62.2 mg, 0.4 mmol), AgOAc (1.3401 g, 8.0 mmol), K₂HPO₄ (766.4 mg, 4.4 mmol), NaHCO₃ (672.0 mg, 8.0 mmol), and 20 mL of C₆F₅CF₃ followed by 1.0 mL of ethyl acrylate. The mixture was frozen with a dry ice/acetone bath. The reaction tube was evacuated and back-filled with O₂ (3 times, balloon) and heated to 120 °C (oil bath) for 20 hours under vigorous stirring. Upon completion, the reaction mixture was cooled to room temperature. The reaction mixture was diluted with ethyl acetate and then filtered through a small pad of Celite. The solvents were removed under reduced pressure and the resulting mixture was purified by column chromatography on silica gel (hexanes/ethyl acetate = 10/1 ~ 2:1) to afford 1.4814 g of **2a** (86%) and 353.8 mg of **L14** (82%).

2.5 Procedure for Cleavage of Auxiliary


(E)-diethyl 5,5-dimethylhept-2-enedioate (3a)



To an oven dried 50 mL Schlenk-type tube equipped with a magnetic stir bar were added lactam (128.8 mg, 0.30 mmol) and 1 mL of anhydrous THF. After cooling to -78 °C, LiHMDS (0.5 M in 2-methyltetrahydrofuran, 1.5 mL, 0.75 mmol) was added dropwise within 5 minutes. The mixture was warmed up to -20 °C naturally in 40 minutes. Then Boc₂O (0.24 mL, d = 0.95 g/mL, 1.05 mmol) was added in -78 °C followed by warming up to room temperature naturally in 2 hours. EtOH (2 mL) and KO^tBu (168.3 mg, 1.5 mmol) were added at room temperature. After stirring at room temperature for 5 hours, the reaction was quenched with saturate NH₄Cl (5 mL) and extracted with ethyl acetate (6 mL × 3). The combined organic layer was washed with brine and dried over MgSO₄, filtrated and concentrated. The crude product was purified by preparative TLC using hexanes/EtOAc (10/1) as the eluent to afford 52.2 mg of **3a** (72%) as colorless oil. ¹H NMR (400 MHz, CDCl₃) δ 7.21-6.92 (m, 1 H), 5.85 (dt, *J*₁ = 15.6 Hz, *J*₂ = 1.3 Hz, 1 H), 4.19 (q, *J* = 7.2 Hz, 2 H), 4.13 (q, *J* = 7.2 Hz, 2 H), 2.25 (dd, *J*₁ = 8.0 Hz, *J*₂ =

1.2 Hz, 2 H), 2.21 (s, 2 H), 1.30 (t, $J = 7.2$ Hz, 3 H), 1.26 (t, $J = 7.2$ Hz, 3 H), 1.05 (s, 6 H); ^{13}C NMR (150 MHz, CDCl_3) δ 172.6, 167.2, 146.2, 125.0, 61.0, 60.9, 46.6, 45.2, 34.7, 28.2, 15.11, 15.09; HRMS (ESI-TOF) Calcd for $\text{C}_{13}\text{H}_{23}\text{O}_4$ $[\text{M}+\text{H}]^+$: 243.1596; found: 243.1594.


2.6 Procedure for Construction of Poly-functionalized Quaternary Carbon Centers



4,4-dimethyl-1-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)piperidine-2,6-dione (**4a**)


To an oven dried 350 mL Schlenk-type tube (with a Teflon high pressure valve and side arm) equipped with a magnetic stir bar were added substrate **1a** (1.3207 g, 4.0 mmol), $\text{Pd}(\text{OAc})_2$ (89.8 mg, 0.4 mmol), **L15** (215.3 mg, 0.8 mmol), *Di*-tert-butyl peroxide (1.47 mL, $d = 0.794$ g/mL, 1.1698 g, 8 mmol), AgOAc (1.3350 g, 8.0 mmol), KH_2PO_4 (1.0887 g, 8.0 mmol) and 20 mL of hexanes. The mixture was frozen with a dry ice/acetone bath. The reaction tube was evacuated and back-filled with CO (3 times, balloon) and heated to $150\text{ }^\circ\text{C}$ (oil bath) for 20 hours under vigorous stirring. Upon completion, the reaction mixture was cooled to room temperature. The reaction mixture was diluted with ethyl acetate and then filtered through a small pad of Celite. The solvents were removed under reduced pressure and the resulting mixture was purified by column chromatography on silica gel (hexanes/ethyl acetate = 15/1) to afford 873.2 mg of **6a** (61%) as yellow solid. ^1H NMR (400 MHz, CDCl_3) δ 2.74 (s, 4 H), 1.24 (s, 6 H);

^{13}C NMR (150 MHz, CDCl_3) δ 169.7, 45.9, 29.6, 27.5; HRMS (ESI-TOF) Calcd for $\text{C}_{14}\text{H}_{11}\text{F}_7\text{NO}_2$ $[\text{M}+\text{H}]^+$: 358.0672; found: 358.0673.



3,3-dimethyl-5-oxo-5-[2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenylamino]-pentanoic acid methyl ester (5a)


To a 100 mL of round bottle flask was added **6a** (714.4 mg, 2.0 mmol), MeOH (15 mL) and KO^tBu (336.6 mg, 3.0 mmol). The mixture was stirred at room temperature for 6 hours. Upon completion, the reaction was quenched with sat. NH_4Cl and extracted with EtOAc (15 mL \times 3). The organic layer was washed with brine and dried over MgSO_4 , filtrated and concentrated. The crude product was purified by column chromatography on silica gel (hexanes/ethyl acetate = 4/1) to afford 708.9 mg of **7a** (91%) as white solid. ^1H NMR (400 MHz, CDCl_3) δ 9.15 (br s, 1 H), 3.77 (s, 3 H), 2.54 (s, 2 H), 2.46 (s, 2 H), 1.14 (s, 6 H); ^{13}C NMR (150 MHz, CDCl_3) δ 174.8, 168.9, 52.2, 46.7, 44.4, 34.1, 28.9; HRMS (ESI-TOF) Calcd for $\text{C}_{15}\text{H}_{15}\text{F}_7\text{NO}_3$ $[\text{M}+\text{H}]^+$: 390.0940; found: 390.0939.



Ethyl 2-(4-(2-methoxy-2-oxoethyl)-4-methyl-6-oxo-1-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)piperidin-2-yl)acetate (2h)

To an oven dried 250 mL Schlenk-type tube (with a Teflon high pressure valve and side arm) equipped with a magnetic stir bar were added substrate **7a** (389.3 g, 1.0 mmol), $\text{Pd}(\text{OAc})_2$ (22.5 mg, 0.1 mmol), **L15** (107.7 mg, 0.4 mmol), TEMPO (15.6 mg, 0.1 mmol), AgOAc (334.0 mg, 2.0 mmol), K_2HPO_4 (191.6 mg, 4.4 mmol), NaHCO_3 (168.0 mg, 2.0 mmol), and 5 mL of $\text{C}_6\text{F}_5\text{CF}_3$ followed by 0.43 mL of ethyl acrylate. The mixture was frozen with a dry ice/acetone bath. The reaction tube was evacuated and

back-filled with O₂ (3 times, balloon) and heated to 120 °C (oil bath) for 20 hours under vigorous stirring. Upon completion, the reaction mixture was cooled to room temperature. The reaction mixture was diluted with ethyl acetate and then filtered through a small pad of Celite. The solvents were removed under reduced pressure and the resulting mixture was purified by column chromatography on silica gel (hexanes/ethyl acetate = 10/1) to afford 332.1 g of **2h** (68%) as yellow oil. The isomeric ratio (major/minor) was determined to be 1:1 by ¹H NMR. ¹H NMR (400 MHz, CDCl₃) δ 4.45-4.30 (m, 1 H), 4.05-3.91 (m, 2 H), 3.72 (s, 1.5 H), 3.71 (s, 1.5 H), 2.70-2.15 (m, 7 H), 1.88 (t, *J* = 12.6 Hz, 0.5 H), 1.73 (dd, *J*₁ = 14.0 Hz, *J*₂ = 11.2 Hz, 0.5 H), 1.35-1.10 (m, 6 H); ¹³C NMR (150 MHz, CDCl₃) δ 171.2, 170.9, 169.6, 169.5, 169.3, 169.1, 61.14, 61.12, 53.31 (d, *J* = 2.7 Hz), 53.10 (d, *J* = 2.7 Hz), 51.71, 51.66, 46.5, 45.0, 43.7, 40.9, 40.08, 40.06, 39.6, 39.5, 32.2, 32.0, 27.2, 22.5, 13.90, 13.89; HRMS (ESI-TOF) Calcd for C₂₀H₂₁F₇NO₅ [M+H]⁺: 488.1308; found: 488.1306.







(E)-5-(2-oxo-2-(2,3,5,6-tetrafluoro-4-(trifluoromethyl)phenyl)amino)ethyl-5-methyl-2-heptenedioic acid 1-ethyl 7-methyl ester (6a)



To an oven dried 50 mL Schlenk-type tube equipped with a magnetic stir bar were added lactam (49.1 mg, 0.1 mmol) and 1 mL of anhydrous THF. After cooling to -78 °C, LiHMDS (0.5 M in 2-methyltetrahydrofuran, 1.0 mL, 0.50 mmol) was added dropwise within 5 minutes. The mixture was warmed up to -20 °C naturally in 40 minutes. Then the reaction was quenched with sat. NH₄Cl/AcOH (V/V = 20/1, 2 mL) in -78 °C and extracted with ethyl acetate (6 mL × 3). The combined organic layer was washed with brine and dried over MgSO₄, filtrated and concentrated. The crude product was purified by preparative TLC using hexanes/EtOAc (3/1) as the eluent to afford 45.7 mg of **8a** (93%) as yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 9.06 (s, 1 H), 7.04-6.90 (m, 1 H), 5.93 (dt, *J*₁ = 15.6 Hz, *J*₂ = 1.4 Hz, 1 H), 4.21 (q, *J* = 7.1 Hz, 2 H), 3.77 (s, 3 H), 2.63 (d, *J* = 12.8 Hz, 1 H), 2.58 (d, *J* = 13.2 Hz, 1 H), 2.52 (d, *J* = 14.0 Hz, 1 H), 2.48 (d, *J* = 14.0 Hz, 1 H), 2.41-2.25 (m, 2 H), 1.30 (t, *J* = 7.2 Hz, 3 H), 1.15 (s, 3 H); ¹³C NMR (150 MHz, CDCl₃) δ 174.1, 168.6, 166.0, 142.8, 125.7, 60.4, 52.2, 44.7, 43.2, 42.8, 37.1, 25.5, 14.2; HRMS (ESI-TOF) Calcd for C₂₀H₂₁F₇NO₅ [M+H]⁺: 488.1308; found: 488.1307.

3. Reference:

1. Sridharan, V.; Ruiz, M.; Menéndez, J. C. *Synthesis* **2010**, 1053.
2. Zhang, Q.; Zhang, Z.; Yan, Z.; Liu, Q.; Wang, T. *Org. Lett.* **2007**, 9, 3651.













7.312
7.308
7.304
7.296
7.291
7.287
7.276
7.273
7.270
7.267
7.257
7.251
7.247
7.243
7.229
7.211
7.205
7.201
7.195
7.188
7.184
7.181
7.010



2.805
2.772
2.720
2.687
2.335
2.299
2.271
2.235
1.599
1.536
1.533
1.517
1.511
1.499
1.492
1.480
1.474
1.456
1.037
1.001
0.983
0.964
0.000







169.496
138.125
130.732
127.964
126.242
77.211 CDCl3
77.000 CDCl3
76.788 CDCl3
44.867
44.328
37.565
31.724
24.202
8.355























7.264



6.702

2.311

1.590

1.117

0.000







169.840



77.212 CDCl3
77.000 CDCl3
76.789 CDCl3



50.112



31.174
29.658































4.381
4.366
4.352
4.338
4.324
4.309
4.041
4.024
4.014
4.006
4.001
3.996
3.988
3.983
3.978
3.973
3.965
3.960
3.956
3.947
3.938
3.920
2.496
2.481
2.457
2.454
2.443
2.440
2.440
2.428
2.410
2.404
2.400
2.388
2.386
2.358
2.013
2.007
1.999
1.994
1.978
1.973
1.965
1.960
1.737
1.709
1.703
1.675
1.659
1.411
1.207
1.188
1.171
1.129
0.000



170.092
169.769



77.211 CDCl3
77.000 CDCl3
76.788 CDCl3

61.059
53.567
53.548
45.708
41.990
40.275
30.430
29.772
24.467
13.886




7.266


4.368
4.354
4.340
4.325
4.286
4.271
3.995
3.992
3.982
3.977
2.443
2.428
2.380
2.364
2.146
2.138
2.133
2.126
2.111
2.104
2.099
2.091
1.997
1.991
1.984
1.978
1.963
1.957
1.950
1.944
1.614
1.409
1.195
1.187
1.136
1.046
0.960
0.944
0.941
0.925
0.907





170.390
170.157
169.802
169.754



77.211 CDCl3
77.000 CDCl3
76.788 CDCl3
61.074
53.445
53.426
53.166
53.147
44.799
43.815
40.375
40.271
40.018
39.571
35.701
32.440
32.372
29.351
26.295
21.416
13.928
13.909
8.065
7.584





4.322
4.305
4.293
4.278
4.264
4.249
4.028
4.024
4.019
4.010
4.006
3.992
3.988
3.978
3.974
3.970
2.455
2.446
2.434
2.429
2.417
2.346
2.303
2.116
2.109
2.104
2.096
2.082
2.074
2.070
2.062
1.603
1.574
1.567
1.553
1.548
1.540
1.534
1.437
1.418
1.391
1.372
1.213
1.195
1.177
0.933
0.915
0.896
0.892
0.874
0.855
0.000





170.438
169.740

77.212 CDCl3
77.000 CDCl3
76.788 CDCl3



61.044
52.976
52.957
42.591
40.295
37.756
34.790
30.745
25.581
13.903
7.495
7.134





-7.267



4.383
4.367
4.355
4.340
4.327
4.312
4.303
4.288
4.274
4.260
4.246
4.231
4.025
4.014
4.010
4.007
3.996
3.993
2.485
2.468
2.457
2.438
2.427
2.410
2.369
2.028
2.021
1.994
1.986
1.648
1.630
1.619
1.595
1.215
1.197
1.179
0.958
0.938
0.919



171.261
171.094
169.779
169.751

77.212 CDCl3
77.000 CDCl3
76.788 CDCl3



61.087
61.059
53.476
52.829
52.812
45.039
44.663
40.593
40.280
40.099
39.129
36.609
36.470
35.486
27.720
27.466
26.402
26.276
26.179
25.894
25.596
25.535
25.485
25.356
13.939
7.980
7.511



-7.267



4.389
4.383
4.371
4.362
3.975
3.969
3.381
3.376
3.209
3.187
3.154
3.131
2.703
2.660
2.452
2.419
2.377
2.327
2.284
2.206
1.933
1.904
1.694
1.664
1.634
1.206
1.188
1.160
1.103



-0.000



170.284
170.086
169.849
169.766

80.765
78.463
77.212 CDCl3
77.000 CDCl3
76.789 CDCl3
61.063
61.038
59.398
59.293
53.536
53.517
53.206
53.188
41.847
40.896
40.324
40.301
38.643
37.042
34.125
33.980
25.974
20.660
13.899







7.266

4.342
4.327
4.313
4.299
4.285
4.270
4.000
3.990
3.982
3.972



2.555
2.548
2.513
2.506
2.465
2.438
2.080
2.073
2.067
2.060
2.047
2.039
2.033
2.026
2.026
1.879
1.851
1.845
1.817
1.723
1.719
1.622
1.566
1.208
1.190
1.172
-0.000



170.262
169.813

77.211 CDCl3
76.999 CDCl3
76.788 CDCl3



61.050
54.247
54.228
44.114
40.622
40.396
40.287
40.006
34.685
24.444
23.773
13.906



7.268

4.355
4.340
4.326
4.312
4.298
4.283
4.021
4.014
4.003
3.996
3.986
3.979
3.968
3.961
2.667
2.659
2.624
2.616
2.450
2.442
2.435
2.425
2.288
2.245
2.236
2.214
2.207
2.202
2.194
1.554
1.542
1.536
1.211
1.193
1.175



0.000



170.103
169.796

77.211 CDCl3
76.999 CDCl3
76.788 CDCl3

61.049
52.765
52.746
43.643
40.306
39.457
39.119
32.675
32.399
25.943
21.567
21.421
13.915





-7.274

4.373
4.358
4.344
4.330
4.316
4.301
4.011
4.003
3.994
3.986
3.773
3.768
3.756

2.853
2.845
2.810
2.802
2.479

2.470
2.466
2.463
2.453
2.373
2.330
2.303
2.295
2.290
2.282
2.268
2.260
2.255
2.247
1.705
1.699
1.214
1.197
1.179

-0.000





169.589
169.213

77.211 CDCl3
77.000 CDCl3
76.788 CDCl3

63.346
61.156
52.433
52.414
42.450
40.064
39.689
38.419
32.762
30.410

13.891





-7.270

4.363
4.348
4.333
4.318
4.303
4.288
4.273
4.027
4.009
3.911
3.876
3.714
3.564

2.805
2.797
2.762
2.754
2.489
2.481
2.475
2.286
2.258
2.250
1.800
1.649
1.645
1.639
1.627
1.219
1.201
1.183

-0.000





169.502
169.437
168.543
168.508
155.786
155.701
155.550
155.464
155.312
155.226
155.075
154.990

119.221
117.314
115.406
113.499

77.211 CDCl3
77.000 CDCl3
76.788 CDCl3



61.316
61.303
52.466
52.447
52.359
52.341
41.857
41.653
41.630
41.378
41.355
39.756
39.285
39.064
38.973
38.873
38.224
37.221
32.453
31.531
31.381
31.344
13.915



7.383
7.379
7.369
7.353
7.341
7.338
7.326
7.321
7.304
7.298
7.291
7.285
7.280
7.257

4.989
4.350
4.336
4.321
4.306
4.292
4.277

2.490
2.479
2.463
2.427
2.422
2.385
2.379
2.366
2.323
1.958
1.952
1.945
1.939
1.924
1.917
1.911
1.905
1.695
1.668
1.666
1.662
1.648
1.633
1.151
1.086
0.000





170.091
169.447

134.915
128.648
128.632
128.471

77.211 CDCl3
77.000 CDCl3
76.788 CDCl3
66.849

53.545
53.526
45.697
41.737
40.098
30.378
29.707
24.421





7.269

4.458
4.443
4.429
4.415
4.401
4.386

2.561
2.546
2.399
2.393
2.381
2.335
2.327
2.316
2.309
2.298
2.291
2.279
2.273
2.024
2.017
2.011
2.005
1.990
1.983
1.977
1.971
1.568
1.539
1.536
1.506
1.185
1.107
0.960
0.941
0.923

0.000





207.178



170.269

77.212 CDCl3
77.000 CDCl3
76.789 CDCl3

52.697
52.679
47.553
45.831
42.145
36.683
30.460
29.804
24.464

7.244







— 7.268

4.201
4.188
4.175
4.161
4.148
4.137

2.507
2.503
2.496
2.492
2.487
2.463
2.459
2.454
2.110
2.106
2.099
2.094
2.077
2.073
2.063
2.058
1.903
1.872
1.840
1.186

— 0.000



— 169.733



— 115.162



77.211 CDCl3
76.999 CDCl3
76.788 CDCl3



52.952
52.927



45.525
41.457

30.235
29.826
24.296
24.283











7.269

4.432
4.418
4.404
4.389
4.383
4.371
4.355
4.341
4.326
3.989
3.720
3.712
2.624
2.563
2.468
2.455
2.449
2.439
2.436
2.407
2.400
2.389
2.385
2.187
2.179
2.174
1.905
1.873
1.842
1.763
1.735
1.728
1.700
1.287
1.222
1.194
1.185

0.000



171.158
170.909
169.641
169.467
169.314
169.067

77.211
76.999 CDCl3
76.788 CDCl3

61.138
61.120
53.323
53.305
53.108
53.090
51.712
51.664
46.473
45.016
43.739
40.882
40.084
40.064
39.564
39.489
32.237
32.032
27.211
22.482
13.902
13.885

